GlaxoSmithKline S.A.E

E£379.00As of Sun 8 Nov 2026, 12:00 UTC
EGX:BIOCHealthcare
Country Egypt
PE (Fwd) •••
TSR 10Y CAGR 46.87%
Div yield 0.20%
ROE 9.15%
Pharmaceutical Preparations
Beta (5Y) 0.30
PE TTM 163.0
TSR TTM 440.29%
Mkt cap E£31.65B
ROIC 12.27%
SE Grade™
Value
Quality
Moat
Consensus
Reference
E£493
29.99%
(42.03%)
Sell 3|2|5|2|2
4Q25
1Q26
2Q26
3Q26
Earnings per shareE£
3.84
3.65
3.71
3.88
16.32%
6.51%
1.98%
8.77%
RevenueE£B
1.821
1.864
1.891
1.966
6.57%
8.99%
13.79%
11.57%
Peers (US$489.7M)
Cap (US$)
PE
472.0M
70.32x
Capital
TTM
5Y
10Y
Leveragex
0.744
0.398
0.291
EBIT/Intx
5.163
0.155
0.172
Own earn%
(276.16)
(53.38)
(77.80)
Sh yield%
21.50
41.90
42.29
Owners
Insiders/Inst%
3.30
51.91
Short interest%
1.95
SBC / revenue%
3.75
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
6
Op margin range%
24–32
$1 testx
—
Incr. ROIC%
60